Helixmith Appoints Dr. Park Young-joo as New Head of U.S. Corporation

Park Young-joo, the new head of Helixmith's U.S. branch.

[Asia Economy Reporter Lee Gwan-joo] Helixmith announced on the 9th that Dr. Park Young-joo, who has been working as the head of clinical development, has been appointed as the head of Helixmith's US branch.

CEO Park Young-joo earned a master's and doctoral degree in statistical epidemiology from Seoul National University Graduate School of Public Health and has continuously worked in the pharmaceutical and bio industries, especially building expertise in the field of clinical trials.

From 1996, for 20 years, she gained diverse experience across all areas of clinical development including clinical trial planning, data management, biostatistics, safety management, MW (Medical Writing), and global clinical management at global pharmaceutical companies MSD and Sanofi.

Since joining Helixmith in 2020, CEO Park has led the clinical division, particularly US clinical trials, alongside Helixmith CEO Kim Sun-young.

CEO Kim Sun-young evaluated, "Dr. Park has high expertise in clinical trials and understands the operational details well. She is especially a professional with cost-efficient thinking and a very strong sense of responsibility for her work."

Since last November, CEO Kim has focused on business development tasks such as licensing of Enzygenesis (VM202), preparation for marketing approval, and market entry preparation, and will continue to work as a team leader on medical science and development strategy among various clinical development tasks.

This content was produced with the assistance of AI translation services.